Targeting Human Astrocytes' Calcium-sensing Receptors for Treatment of Alzheimer's Disease

Title:Targeting Human Astrocytes' Calcium-sensing Receptors for Treatment of Alzheimer's Disease

Volume: 23 Issue: 33

Author(s): Anna Chiarini, Ubaldo Armato*, James F. Whitfield and Ilaria Dal Pra

Affiliation:

• Human Histology & Embryology Unit, University of Verona Medical School, Verona, Venetia,Italy

Keywords: Alzheimer's disease, calcium-sensing receptor, calcilytics, amyloid-β, amyloid precursor protein, human astrocytes, vascularendothelial growth factor-A, tau protein.

Abstract: Understanding the pathophysiology of Alzheimer's disease (AD) in the principal human neural cells is necessary for finding therapeutics for this illness. To help do this, we have been using freshly cultured functionally normal cerebral cortical adult human astrocytes (NAHAs) and postnatal neurons. The findings show that amyloid-β oligomers (Aβ-os) binding to calcium-sensing receptors (CaSRs) on NAHAs and neuron surfaces trigger signals capable of driving AD pathogenesis. This Aβ•CaSR signalling shifts the amyloid precursor protein (APP) from its α-secretase shedding producing neurotrophic/neuroprotective soluble (s)APPα to its β-secretase cleaving engendering AD-driving Aβ42/Aβ42-os peptides. Aβ•CaSR signalling in NAHAs also drives the release of toxic hyper-phosphorylated Tau proteins in exosomes, and of nitric oxide, and VEGF-A. These several harmful agents comprise the neuron-killing machinery, driving the very slowly spreading AD neurocontagion. VEGF-A over-secretion from Aβ-exposed blood vessel-attached astrocytes induces a functional magnetic resonance imaging- detectable hippocampal neoangiogenesis which indicates approaching AD in amnestic minor cognitive impairment (aMCI) patients. Most important in AD's regard, selective allosteric CaSR antagonists (calcylitics) added to Aβ42/Aβ42-os-exposed NAHAs (or to human neuron cultures) rescue the extracellular shedding of neurotrophic/ neuroprotective sAPPα and suppress all the neurotoxic effects of Aβ•CaSR signalling even when multiple microglial cytokines are also present. Therefore, since the multipotent calcilytics would be reasonably safe and inexpensive drugs for humans, it is worthwhile testing them as AD therapeutics in clinical trials especially in persons in the earliest detectable stages of AD neuropathology progression such as aMCI.

Cite this article as:

Chiarini Anna , Armato Ubaldo*, Whitfield F. James and Pra Dal Ilaria, Targeting Human Astrocytes' Calcium-sensing Receptors for Treatment of Alzheimer's Disease, Current Pharmaceutical Design 2017; 23 (33) . https://dx.doi.org/10.2174/1381612823666170710162509